Cargando…
Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients
OBJECTIVE: The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. METHODS: We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube can...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103494/ https://www.ncbi.nlm.nih.gov/pubmed/37055754 http://dx.doi.org/10.1186/s12905-023-02329-9 |
_version_ | 1785025862939181056 |
---|---|
author | Zhang, Nan Zheng, Hong Gao, Yunong Shu, Tong Wang, Hongguo |
author_facet | Zhang, Nan Zheng, Hong Gao, Yunong Shu, Tong Wang, Hongguo |
author_sort | Zhang, Nan |
collection | PubMed |
description | OBJECTIVE: The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. METHODS: We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were diagnosed and treated at the Department of Gynecologic Oncology of Peking University Cancer Hospital between May 2012 and January 2022. RESULTS: A total of 155 patients were eventually enrolled in this study, with 77 as first-line chemotherapy (FL) and 78 as recurrence therapy (RT) among which 37 patients were platinum sensitive and 41 were platinum resistant. Among the 77 patients in the FL group, 35 received bevacizumab during neoadjuvant chemotherapy (NACT) alone (NT), 23 received bevacizumab during both neoadjuvant and first-line chemotherapy (NT + FL) and 19 received bevacizumab during first-line chemotherapy alone (FLA). Among the 43 patients of NT and NT + FL groups undergoing interval debulking surgery (IDS), 38(88.4%) patients achieved optimally debulking and 24 (55.8%) patients had no residual disease after IDS. The patients in the FL group had a median progression free survival (PFS) of 15(95%CI: 9.951–20.049) months, and the 12-month PFS was 61.7%. In the RT group, the overall response rate (ORR) was 53.8%. According to multivariate analysis, the patients' platinum sensitivity had a significant impact on the PFS in the RT group. 13(8.4%) patients discontinued bevacizumab due to toxicity. Seven patients were in the FL group while 4 patients were in the RT group. The most common adverse event associated with bevacizumab therapy was hypertension. CONCLUSION: Bevacizumab is effective and well-tolerated in the real world setting of ovarian cancer treatment. Adding bevacizumab to NACT is feasible and tolerable. Receiving the regimen containing bevacizumab in the last preoperative chemotherapy did not result in increased intraoperative bleeding of IDS. Platinum sensitivity is the most important factor affecting the effectiveness of bevacizumab in recurrent patients. |
format | Online Article Text |
id | pubmed-10103494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101034942023-04-15 Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients Zhang, Nan Zheng, Hong Gao, Yunong Shu, Tong Wang, Hongguo BMC Womens Health Research Article OBJECTIVE: The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. METHODS: We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were diagnosed and treated at the Department of Gynecologic Oncology of Peking University Cancer Hospital between May 2012 and January 2022. RESULTS: A total of 155 patients were eventually enrolled in this study, with 77 as first-line chemotherapy (FL) and 78 as recurrence therapy (RT) among which 37 patients were platinum sensitive and 41 were platinum resistant. Among the 77 patients in the FL group, 35 received bevacizumab during neoadjuvant chemotherapy (NACT) alone (NT), 23 received bevacizumab during both neoadjuvant and first-line chemotherapy (NT + FL) and 19 received bevacizumab during first-line chemotherapy alone (FLA). Among the 43 patients of NT and NT + FL groups undergoing interval debulking surgery (IDS), 38(88.4%) patients achieved optimally debulking and 24 (55.8%) patients had no residual disease after IDS. The patients in the FL group had a median progression free survival (PFS) of 15(95%CI: 9.951–20.049) months, and the 12-month PFS was 61.7%. In the RT group, the overall response rate (ORR) was 53.8%. According to multivariate analysis, the patients' platinum sensitivity had a significant impact on the PFS in the RT group. 13(8.4%) patients discontinued bevacizumab due to toxicity. Seven patients were in the FL group while 4 patients were in the RT group. The most common adverse event associated with bevacizumab therapy was hypertension. CONCLUSION: Bevacizumab is effective and well-tolerated in the real world setting of ovarian cancer treatment. Adding bevacizumab to NACT is feasible and tolerable. Receiving the regimen containing bevacizumab in the last preoperative chemotherapy did not result in increased intraoperative bleeding of IDS. Platinum sensitivity is the most important factor affecting the effectiveness of bevacizumab in recurrent patients. BioMed Central 2023-04-13 /pmc/articles/PMC10103494/ /pubmed/37055754 http://dx.doi.org/10.1186/s12905-023-02329-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Zhang, Nan Zheng, Hong Gao, Yunong Shu, Tong Wang, Hongguo Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients |
title | Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients |
title_full | Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients |
title_fullStr | Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients |
title_full_unstemmed | Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients |
title_short | Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients |
title_sort | real-world study of bevacizumab treatment in patients with ovarian cancer: a chinese single-institution study of 155 patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103494/ https://www.ncbi.nlm.nih.gov/pubmed/37055754 http://dx.doi.org/10.1186/s12905-023-02329-9 |
work_keys_str_mv | AT zhangnan realworldstudyofbevacizumabtreatmentinpatientswithovariancancerachinesesingleinstitutionstudyof155patients AT zhenghong realworldstudyofbevacizumabtreatmentinpatientswithovariancancerachinesesingleinstitutionstudyof155patients AT gaoyunong realworldstudyofbevacizumabtreatmentinpatientswithovariancancerachinesesingleinstitutionstudyof155patients AT shutong realworldstudyofbevacizumabtreatmentinpatientswithovariancancerachinesesingleinstitutionstudyof155patients AT wanghongguo realworldstudyofbevacizumabtreatmentinpatientswithovariancancerachinesesingleinstitutionstudyof155patients |